{"groups":[{"description":"Participants randomized to asciminib 40mg BID","id":"FG000","title":"Asciminib"},{"description":"Participants randomized to bosutinib 500mg QD","id":"FG001","title":"Bosutinib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"28"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"7"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"21"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"7"}],"type":"Subject/Guardian Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Pregnancy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Not treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"157"},{"groupId":"FG001","numSubjects":"76"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"156"},{"groupId":"FG001","numSubjects":"76"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"comment":"One participant randomized to asciminib was discontinued due to cytopenia as per Investigator's decision and never took medication.","type":"Not Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"25"}],"type":"Switched to Receive Asciminib"},{"achievements":[{"groupId":"FG000","numSubjects":"77"},{"groupId":"FG001","numSubjects":"8"}],"comment":"Completed = Completed Treatment","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"80"},{"groupId":"FG001","numSubjects":"68"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Randomization was stratified by major cytogenetic response (MCyR) at screening.","recruitmentDetails":"Participants were treated at a total of 84 sites."}